Kamada Ltd. Net Income 2011-2026 | KMDA

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Kamada Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-2.23 M	17.1 M	22.3 M	22.3 M	6.9 M	-6.73 M	-11.3 M	-13.2 M	400 K	260 K	-3.49 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.3 M	-13.2 M	2.94 M

Quarterly Net Income Kamada Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-845 K	-	-	-	6.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.84 M	-845 K	3 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
AIkido Pharma AIKI	-22.4 M	-	1.93 %	$ 17.4 M	USA
Nymox Pharmaceutical Corporation NYMX	-12.5 M	-	-19.68 %	$ 18.4 M	Canada
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	-1.36 M	$ 0.9	-2.33 %	$ 6.62 M	China
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	67.3 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	226 M	$ 21.96	-0.68 %	$ 3.64 B	USA
RedHill Biopharma Ltd. RDHL	-97.7 M	$ 1.02	-0.49 %	$ 428 M	Israel
Allakos ALLK	-186 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
AlloVir ALVR	-43.4 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Aligos Therapeutics ALGS	-24.2 M	$ 6.4	4.4 %	$ 63.3 M	USA
Applied Therapeutics APLT	-120 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-64.8 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	-30.4 M	-	17.91 %	$ 11.1 M	USA
Avenue Therapeutics ATXI	-2.91 M	-	-52.27 %	$ 4.45 M	USA
Amphastar Pharmaceuticals AMPH	98.1 M	$ 21.41	1.9 %	$ 1 B	USA
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
AstraZeneca PLC AZN	115 M	-	-	$ 96.9 B	Britain
BioDelivery Sciences International BDSI	84.9 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
Brainstorm Cell Therapeutics BCLI	-10.3 M	-	-2.5 %	$ 5.88 M	USA
Kazia Therapeutics Limited KZIA	-24.6 M	$ 12.26	3.72 %	$ 1.62 B	Australia
AgeX Therapeutics AGE	-19.2 M	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	10.3 B	$ 105.46	-0.09 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	287 M	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	-83.8 M	$ 4.08	0.25 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	-16.1 M	$ 23.26	1.75 %	$ 2.96 B	USA
Cara Therapeutics CARA	-18.2 M	-	-3.03 %	$ 260 M	USA
Autolus Therapeutics plc AUTL	-288 M	$ 1.44	-5.88 %	$ 383 M	Britain
Aptose Biosciences APTO	-25.5 M	-	-45.71 %	$ 1.2 M	Canada
BioXcel Therapeutics BTAI	-69.9 M	$ 1.06	-3.64 %	$ 12.9 M	USA
CASI Pharmaceuticals CASI	-36.7 M	-	-	$ 35.4 M	USA
AVROBIO AVRO	12.2 M	-	1083.1 %	$ 745 M	USA
Cabaletta Bio CABA	-168 M	$ 2.95	-3.28 %	$ 296 M	USA
Can-Fite BioPharma Ltd. CANF	-9.83 M	$ 2.91	-1.36 %	$ 4.79 M	Israel
bluebird bio BLUE	-212 M	-	-	$ 546 M	USA
CymaBay Therapeutics CBAY	-105 M	-	-	$ 3.45 B	USA
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA